E N D
1. Voluntary counseling and Testing in Pakistan Mr. (Dr.) Nadeem Ikram
MBBS, DCP, FCPS (IMMUNOLOGY)
National HIV/STI Referral Lab
NACP, NIH, Chak Shahzad
Islamabad, Pakistan
2. Country Profile Population (2005) 159,196,336
Provinces 4
Area 2 , AJK
Languages - Urdu
Area: 796,095 sq km
Currency Pak Rupee
Capital - Islamabad
Ethnic composition - Muslims 97%
3. Location: Southern Asia, India on the east, Iran and Afghanistan on the west, China in the north and the Arabian sea in the south.
4. Epidemiological Profile
Estimated Prevalence: 0.1%
NACP/MOH (using WHO/UNAIDS EPI Forecast Model)
estimates the number to be approximately
80,000
5. Current epidemiological trends Shift from low prevalence into concentrated stage HIV prevalence among IDUs and MSWs more than 5%
In 2004, 2005 & 2006 predominant mode of transmission is I/V drug use (IBBS data)
Increasing number of individuals being reported with HIV; men who have sex with men, hijras, female sex workers
Increasing numbers of individuals having signs and symptoms related to early HIV infection are being reported to health care facilities
6. Round One Surveillance Results
7. Implications of the change HIV transmission through injecting drug use is highly dynamic explosive spread
Drug user population is highly mobile
Drug user population is not isolated and has links with other vulnerable populations in addition to general population (are married)
Donate blood for money (paid donors)
Burden on health systems
Poor infection control practices
High risk groups to general population
Youth vulnerability- high
8. Key Risk Factors in Pakistani Scenario Low literacy rates
Silence and denial
High Poverty levels
Low spending on health and education
High prevalence of risky behaviors
Large number of internal and external migrants
A high proportion of adolescents and young adults
Gender inequalities
9. Laboratory networks Central level : National Referral Laboratory
Secondary level: Provincial Laboratories
Primary level : VCT, ANC,TB, STI clinics
Strengthen communication and collaboration between all levels in the network
10. STRATEGIES STRATEGY I : Single assay
Screening
STRATEGY II : 2 different assays
Surveillance
STRATEGY III : 3 different assays
Diagnosis
11. Strategy III Pre-requisites Informed consent: Mandatory
Testing is optional & voluntary
Pre- and post-test counseling:
Prepare for possible emotional trauma
Complete confidentiality:
of the test as well as of the individual
12. Achievements to date Establishment of 16 VCT centres (both community based and hospital based) for general population
VCT is an integral component of service delivery package( SDP) of 20 projects currently being implemented for most at risk population IDUs, FSWs, MSW/Hijra, truckers, jail inmates.
46 surveillance Centers for general population
Quarterly reports from surveillance centers and blood banks data.
13. Achievements to date Operationalisation of nine ARV treatment centers.
Strengthening of blood transfusion services. Guidelines for QC in blood banking
Human resource development - doctors and nurses in management of STIs and AIDS patients
Procurement of drugs for STIs, OIs and ARV
Service delivery to HRGs - scaling up still remains a challenge
Advocacy/sensitization sessions for parliamentarians, political influentials, religious leaders, district government and policy makers
14. CHALLENGES Varying level of political commitment at provincial & district level
Limited non health sector involvement
Limited private sector involvement
General lack of access to information and resources on HIV/AIDS
Difficult accessibility of high risk groups
Local data on specific behavioural vulnerabilities of HRGs
Access to youth both in-school & out-of-school
Large un-regulated private sector catering to 60% of population needs
Strengthening of BTS infrastructure
15. CHALLENGES Epidemiological modeling based on available data
Stigma related to STIs and myths and misconceptions related to STIs
pilot projects focusing on sexual and reproductive health for youth
Further need for multisectoral involvement in HIV/AIDS prevention activities
Stigma and discrimination of PLWHA
Strengthening of M&E plans for Programme implementation
Availability of all regimens of ARV and their regular supplies
High cost of treatment, diagnostics and treatment monitoring.